ANB-10 is under clinical development by Biocad and currently in Phase II for Hemophilia A (Factor VIII Deficiency). According to GlobalData, Phase II drugs for Hemophilia A (Factor VIII Deficiency) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANB-10’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANB-10 is under development for the treatment of hemophilia A. It is a gene therapy. It is a gene therapy delivered using vector AAV5 to deliver optimized B-domain deleted (BDD) factor VIII transgene. It is administered through intravenous route.
JSC Biocad (Biocad) is a biotechnology company that conducts research and development services. The company develops, manufactures, and distributes generic pharmaceutical products. Its products portfolio comprise rituximab, bevacizumab, trastuzumab, prolgolimab, levilimab, netakimab and eculizumab. Biocad develops products in the form of suppositories, spray, and drops. The compay provides products under the brands Avegra, Herticad, Gerticad, Forteka, Extimia and Leucostim. It manufactures products in the therapeutic areas such as oncology, rare disease, autoimmune diseases, and infectious diseases. The company’s R&D centers are located in Lyubuchany, Neudorf and Frontovaya. It operates in Brazil, China, Russia, the UAE and Vietnam. Biocad is headquartered in Saint-Petersburg, Russia.
For a complete picture of ANB-10’s drug-specific PTSR and LoA scores, buy the report here.